Preclinical predictors of anticancer drug efficacy: Critical assessment with emphasis on whether nanomolar potency should be required of candidate agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 572-578

  Wong, C C ^a   Cheng, Ka Wing ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULINDAC; SULINDAC SULFIDE; TAMOXIFEN; THALIDOMIDE; VALDECOXIB; VALPROIC ACID;

ADENOMA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; COLON ADENOMA; COLON CANCER; COLON POLYP; COLORECTAL CANCER; COLORECTAL POLYP; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAMILIAL COLON POLYPOSIS; FIBROSARCOMA; HEAD AND NECK CANCER; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THROMBOSIS; UTERINE CERVIX CANCER; UTERUS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; MODELS, MOLECULAR; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE;

EID: 84861539740     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.191957     Document Type: Review

References (55)

1. Arber N (2000) Do NSAIDs prevent colorectal cancer? Can J Gastroenterol 14:299-307.
2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899. (Pubitemid 36297997)
3. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, et al. (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131:1674-1682. (Pubitemid 44958508)
4. Bauer KS, Dixon SC, and Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834. (Pubitemid 28305265)
5. Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40:852-857.
6. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102. (Pubitemid 40365350)
7. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, et al. (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 15:2479-2487.
8. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, et al. (2010) Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16:1442-1451.
9. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, and Dalgleish AG (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172. (Pubitemid 35418112)
10. Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, et al. (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848-855. (Pubitemid 351398075)
11. Elwood PC, Gallagher AM, Duthie GG, Mur LA, and Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373:1301-1309.
12. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, et al. (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239-1247.
13. Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, et al. (2008) The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 14:2088-2094. (Pubitemid 351551120)
14. Fiebig HH, Maier A, and Burger AM (2004) Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40:802-820. (Pubitemid 38519759)
15. Fournier DB and Gordon GB (2000) COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl 34:97-102. (Pubitemid 30176739)
16. Franks ME, Macpherson GR, and Figg WD (2004) Thalidomide. Lancet 363:1802-1811. (Pubitemid 38698386)
17. Fries S and Grosser T (2005) The cardiovascular pharmacology of COX-2 inhibition. Hematol Am Soc Hematol Educ Program 2005:445-451.
18. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, et al. (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 312:1206-1212. (Pubitemid 40293782)
19. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978. (Pubitemid 34062289)
20. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, Favaretto A, Daniele B, Galetta D, et al. (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500-512. (Pubitemid 46805905)
21. Hann MM (2011) Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2:349-355.
22. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950.
23. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, and Sugihara K (2003) A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9:4756-4760. (Pubitemid 37323278)
24. Holbeck SL, Collins JM, and Doroshow JH (2010) Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 9:1451-1460.
25. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, et al. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
26. Hutchinson L and Kirk R (2011) High drug attrition rates-where are we going wrong? Nat Rev Clin Oncol 8:189-190.
27. Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, and Gerner EW (2008) Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer 60 (Suppl 1):30-35.
28. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431. (Pubitemid 32522115)
29. Kashfi K and Rigas B (2005) Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70:969-986. (Pubitemid 41262072)
30. Keiser MJ, Irwin JJ, and Shoichet BK (2010) The chemical basis of pharmacology. Biochemistry 49:10267-10276.
31. Kumar S, Witzig TE, and Rajkumar SV (2004) Thalidomid: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22:2477-2488. (Pubitemid 41115407)
32. Labayle D, Boyer J, Drouhin F, Zarka Y, and Fischer D (1994) Sulindac in familial adenomatous polyposis. Lancet 343:417-418.
33. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, and Anderson KC (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17:41-44. (Pubitemid 36175886)
34. Marchion DC, Bicaku E, Daud AI, Sullivan DM, and Munster PN (2005) Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65:3815-3822. (Pubitemid 40616361)
35. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32-38.
36. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, et al. (2010) Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 28:4575-4580.
37. Münster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, and Sullivan D (2009) Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 15:2488-2496.
38. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, et al. (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25:1979-1985. (Pubitemid 46972780)
39. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, et al. (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:2070-2076.
40. O'Byrne KJ, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D, and Ranson M (2007) Combination therapy with gefitinib and rofecoxib in patients with platinum- pretreated relapsed non small-cell lung cancer. J Clin Oncol 25:3266-3273. (Pubitemid 47325611)
41. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092. (Pubitemid 19175145)
42. Rahman YE, Cerny EA, Tollaksen SL, Wright BJ, Nance SL, and Thomson JF (1974) Liposome-encapsulated actinomycin D: potential in cancer chemotherapy. Proc Soc Exp Biol Med 146:1173-1176.
43. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890. (Pubitemid 36297996)
44. Sausville EA and Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66:3351-3354, discussion 3354.
45. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G, and Grösch S (2008) The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 76:179-187.
46. Shackleton M, Quintana E, Fearon ER, and Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138:822-829.
47. Sharpless NE and Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754. (Pubitemid 44323701)
48. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813-823.
49. Siegel R, Ward E, Brawley O, and Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236.
50. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952. (Pubitemid 30419089)
51. Suggitt M and Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11:971-981. (Pubitemid 40175744)
52. Teicher BA (2006) Tumor models for efficacy determination. Mol Cancer Ther 5:2435-2443.
53. Teo SK, Stirling DI, and Zeldis JB (2005) Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 10:107-114. (Pubitemid 40247808)
54. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96:7563-7568. (Pubitemid 29299702)
55. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, and Epstein J (2002) Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 100: 4162-4168. (Pubitemid 35396884)